Template:Chemical SUIT-034 NADH mt D082: Difference between revisions
From Bioblast
No edit summary |
No edit summary |
||
| Line 25: | Line 25: | ||
| 6Myx | | 6Myx | ||
| {{Template:Myxothiazol}} | | {{Template:Myxothiazol}} | ||
| We do not recommend the use of any other inhibitor of complex III, like {{Template:Antimycin A}}, due to background fluorescence. | | We do not recommend the use of any other inhibitor of complex III, like {{Template:Antimycin A}}, due to the chemical background effect on fluorescence. | ||
|- | |- | ||
| 7Reox | | 7Reox | ||
Revision as of 16:27, 14 December 2023
| Step | Chemical(s) and link(s) | Comments |
|---|---|---|
| 1D.1 | ADP (D) | |
| 2PGM | Pyruvate (P), Glutamate (G), and Malate (M) | |
| 3D2.5 | ADP (D) | |
| 4U | SF6847 | We do not recommend the use of any other uncoupler, like Carbonyl cyanide m-chlorophenyl hydrazone, CCCP (U), due to background fluorescence. |
| 5Anox | The O2 concentration in the O2k-chamber can be decreased by N2 or H2 injection to reach faster anoxia, see: Setting the oxygen concentration. | |
| 6Myx | Myxothiazol | We do not recommend the use of any other inhibitor of complex III, like Antimycin A (Ama), due to the chemical background effect on fluorescence. |
| 7Reox |
